Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial
The ZEUS clinical trial found that the anti-inflammatory drug ziltivekimab did not reduce major cardiovascular events in high-risk patients.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Heart researchers at the American Heart Association annual meeting in Chicago unpacked the neutral findings from ZEUS, a major anti-inflammatory clinical trial. According to MedPage Today, the global phase 3 trial tested ziltivekimab, a monoclonal antibody designed to target interleukin-6 (IL-6). While the treatment substantially reduced inflammatory markers, including free IL-6 and high-sensitivity C-reactive protein (CRP), it failed to reduce the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Paul M. Ridker, MD, of Harvard Medical School and Mass General Brigham Hospital reported that over a median follow-up of 33 months, primary endpoint events occurred in 561 patients in the ziltivekimab group and 565 patients in the placebo group. Medical Xpress noted that ZEUS enrolled patients with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation who were a decade older, had significant kidney disease, and often suffered from longstanding diabetes and heart failure compared to populations in earlier successful trials like CANTOS. Ridker explained that in such patients with advanced disease, "the horse may already have been out of the barn," suggesting that targeting a downstream molecule like IL-6 may have been applied to the wrong, highly advanced patient population. BioSpace reported that following the topline results released in July 2026, Novo Nordisk ended several studies of ziltivekimab, including HERMES and ATHENA, but allowed the Phase 3 ARTEMIS trial in acute settings to continue. Discussant Priscilla Hsue, MD, questioned whether the drug was given too late or if targeting the ligand rather than the receptor was the wrong strategy. Despite the neutral trial outcome, researchers emphasized that inflammation remains a critical treatment target. MedPage Today and Medical Xpress reported that clinicians can still utilize lifestyle measures and available drugs such as statins, GLP-1 receptor agonists, and colchicine, which has been shown to reduce cardiovascular risk.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 8d ago.
Quick answers
Did ziltivekimab lower inflammatory markers in the ZEUS trial?
Yes. MedPage Today reported that ziltivekimab produced substantial reductions in free interleukin-6 (IL-6) and high-sensitivity C-reactive protein (CRP).
What were the primary endpoints of the ZEUS trial?
According to MedPage Today, the primary composite endpoint included death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
Which ongoing ziltivekimab trial was allowed to continue after ZEUS?
BioSpace and MedPage Today reported that the Phase 3 ARTEMIS trial in acute settings is continuing.
Coverage (9)
- Ziltivekimab sharply lowered CRP—but the ZEUS trial found no reduction in heart attacks, strokes or cardiovascular deaths Medical Daily · 10d ago
- Dipender Gill Raises Questions About Cardiovascular Risk and IL-6 Inhibition in ZEUS Oncodaily · 10d ago
- Heart association meeting’s readout is trending ‘neutral’ STAT · 10d ago
- Novo’s troubled cardio drug could find niche in less sick patients BioSpace · 10d ago
- ZEUS: What Went Awry With Ziltivekimab in Inflammation—and What Now? TCTMD.com · 10d ago
- Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD MedPage Today · 10d ago
- AHA26: Ziltivekimab shows inflammation control, but no MACE protection FirstWord Pharma · 10d ago
- Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories STAT · 10d ago
- Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial Medical Xpress · 10d ago
Topics
Related trends
Experts spell out what heart health means for women of all ages
New joint heart health guidance from the American Heart Association and three other medical groups urges cardiovascular screening for women at every life stage.
Does a heart stent prevent future heart attacks in stable patients? 25-year follow-up offers new insight
A 25-year follow-up of the COURAGE trial shows routine stenting does not improve long-term survival or reduce heart attacks in stable coronary artery disease patients.
Why heart attacks can still happen even when bad cholesterol is low
New medical coverage explores why heart attacks can still occur in adults who maintain normal, low levels of bad cholesterol.
Common heart pill under scrutiny for older patients as study weighs risks of stopping
The STREAM trial found stopping statins in adults over 70 without prior heart disease led to more heart attacks, strokes, and deaths, yet was declared statistically noninferior due to a permissive margin.
What to do if you, or someone around you, might be having a heart attack
Recent coverage addresses urgent medical guidance on identifying and responding to potential heart attacks.
An unexpected bedroom tool could help stabilize blood sugar: study
A randomized trial found that using a HEPA air purifier in the bedroom at night reduced daily blood sugar swings by nearly 8% in adults with prediabetes.